Wall Street's major averages took weekly gains, with both the S&P 500 and the Dow achieving new all-time high closes as the key jobs report came in line with expectations, and the U.S. Supreme Court ...
In 2025, made or projected biopharma workforce cuts affected about 42,700 employees, according to BioSpace tallies. BioSpace ...
The biotech is developing drugs that target the biology of aging to treat obesity, cardiovascular disease, and more ...
Bio-Techne (TECH) has been drifting after a tough year, but recent gains over the past 3 months suggest investors are rethinking the story as growth and profitability quietly improve. See our latest ...
Collaboration aims to automate RNA and protein detection in 3D tissue specimens, reducing complexity and technical barriers. Innovation has the potential to improve preclinical research by reducing ...
The issuer is solely responsible for the content of this announcement. Collaboration aims to automate RNA and protein detection in 3D tissue specimens, reducing complexity and technical barriers.
Bio-Techne (NASDAQ:TECH) will release its quarterly earnings report on Wednesday, 2025-11-05. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Bio-Techne to report ...
Fintel reports that on October 14, 2025, TD Cowen maintained coverage of Bio-Techne (NasdaqGS:TECH) with a Buy recommendation. Analyst Price Forecast Suggests 12.98% Upside As of September 30, 2025, ...
RNAscope™ technology and the Lunaphore COMET™ enable simultaneous RNA and protein detection on the same tissue section Technologies support spatial multiomic analysis and deeper insights for pathology ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback